Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.

[1]  A. De Soyza,et al.  Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis , 2016 .

[2]  R. Orriols,et al.  Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis , 2015, Respiration.

[3]  Anand K. Gupta,et al.  Non Cystic Fibrosis Bronchiectasis , 2015, The Indian Journal of Pediatrics.

[4]  J. Perry,et al.  Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. , 2015, Respiratory medicine.

[5]  J. Weers.  Inhaled antimicrobial therapy - barriers to effective treatment. , 2015, Advanced drug delivery reviews.

[6]  J. Elborn,et al.  Reclaiming the name ‘bronchiectasis’ , 2015, Thorax.

[7]  W. Guan,et al.  Characterization of Lung Function Impairment in Adults with Bronchiectasis , 2014, PloS one.

[8]  A. O'donnell,et al.  Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores , 2014, Thorax.

[9]  J. Elborn,et al.  Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. , 2014, Respiratory medicine.

[10]  Haiqing Chu,et al.  Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis , 2014, Archives of medical science : AMS.

[11]  F. Martinez,et al.  The role of the microbiome in exacerbations of chronic lung diseases , 2014, The Lancet.

[12]  A. Nicholson,et al.  Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study , 2014, BMC Pulmonary Medicine.

[13]  A. O'donnell,et al.  A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. , 2014, Chest.

[14]  D. Shaw,et al.  Respiratory microbiota: addressing clinical questions, informing clinical practice , 2014, Thorax.

[15]  E. Stovold,et al.  Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review , 2014, European Respiratory Journal.

[16]  T. Welte,et al.  Bronchiectasis-Associated Hospitalizations in Germany, 2005 – 2011: A Population-Based Study of Disease Burden and Trends , 2014 .

[17]  A. O'donnell,et al.  Nebulized colistin for non-cystic fibrosis bronchiectasis: déjà vu all over again? , 2014, American journal of respiratory and critical care medicine.

[18]  M. McGuckin,et al.  A novel microbiota stratification system predicts future exacerbations in bronchiectasis. , 2014, Annals of the American Thoracic Society.

[19]  Sarah Jane Schwarzenberg,et al.  European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[20]  C. Goss,et al.  Inhaled antibiotics for lower airway infections. , 2014, Annals of the American Thoracic Society.

[21]  J. Philley,et al.  Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. , 2014, Respiratory medicine.

[22]  Stefano Aliberti,et al.  The bronchiectasis severity index. An international derivation and validation study. , 2014, American journal of respiratory and critical care medicine.

[23]  T. Nawrot,et al.  Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. , 2014, Respiratory medicine.

[24]  S. Geyer.  Asbestos, asbestosis, smoking, and lung cancer: study bias and confounding issues that complicate the interpretation of the results. , 2014, American journal of respiratory and critical care medicine.

[25]  D. Rodgers,et al.  Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[26]  Darren L. Smith,et al.  Polymicrobial airway bacterial communities in adult bronchiectasis patients , 2013, BMC Microbiology.

[27]  T. Welte,et al.  Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and Trends , 2013, PloS one.

[28]  J. Lordan,et al.  Non-cystic fibrosis bronchiectasis. , 2013, QJM : monthly journal of the Association of Physicians.

[29]  S. Welham,et al.  National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care? , 2013, Thorax.

[30]  Richard C Boucher,et al.  Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. , 2013, American journal of respiratory and critical care medicine.

[31]  Stefan Willmann,et al.  Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study , 2013, Clinical Drug Investigation.

[32]  G. Rogers,et al.  Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition , 2013, Thorax.

[33]  M. Moffatt,et al.  A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis , 2013, European Respiratory Journal.

[34]  M. Tunney,et al.  Macrolides and bronchiectasis: clinical benefit with a resistance price. , 2013, JAMA.

[35]  M. McGuckin,et al.  Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. , 2013, JAMA.

[36]  W. Boersma,et al.  Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.

[37]  Arthur S Slutsky,et al.  Circulating histones: a novel target in acute respiratory distress syndrome? , 2013, American journal of respiratory and critical care medicine.

[38]  A. Hill,et al.  Bronchiectasis: breaking the cycle of inflammation and infection. , 2013, The Lancet. Respiratory medicine.

[39]  A. Hill,et al.  Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. , 2012, American journal of respiratory and critical care medicine.

[40]  L. Smeeth,et al.  P172 Time Trends in Incidence and Prevalence of Bronchiectasis in the UK , 2012, Thorax.

[41]  C. Olveira,et al.  Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score , 2012, European Respiratory Journal.

[42]  N. Karalus,et al.  Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[43]  A. Hill,et al.  Evaluating success of therapy for bronchiectasis: what end points to use? , 2012, Clinics in chest medicine.

[44]  S. Seys,et al.  Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients , 2012, Respiratory Research.

[45]  A. Malin,et al.  Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. , 2012, Respiratory medicine.

[46]  R. Kronmal,et al.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis , 2012, Pediatric pulmonology.

[47]  N. Høiby,et al.  Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[48]  P. Bruinenberg,et al.  113 Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers (HV) and non-cystic fibrosis bronchiectasis (BE) patients , 2011 .

[49]  S. Holland,et al.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. , 2011, Chest.

[50]  A. Davidson,et al.  Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[51]  P. Mogayzel,et al.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. , 2010, Paediatric respiratory reviews.

[52]  I. Du Rand,et al.  Introduction and methods: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[53]  D Bilton,et al.  British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.

[54]  R. Hubbard,et al.  Trends in bronchiectasis mortality in England and Wales. , 2010, Respiratory medicine.

[55]  D. Bilton,et al.  British Thoracic Society guideline for non-CFbronchiectasis , 2010, Thorax.

[56]  E. Sahai,et al.  Integrin-independent movement of immune cells , 2009, F1000 biology reports.

[57]  L. Bentur,et al.  Non-cystic fibrosis bronchiectasis: review and recent advances , 2009, F1000 medicine reports.

[58]  J. Aronson.  Safety , 2009, BMJ : British Medical Journal.

[59]  D. Hansell,et al.  Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.

[60]  R. Coll,et al.  Diagnóstico y tratamiento de las bronquiectasias , 2008 .

[61]  A. O'donnell.  Recent Advances in Chest MedicineBronchiectasis , 2008 .

[62]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[63]  B. Morrissey,et al.  Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. , 2006, Chest.

[64]  Massimiliano Mascherini,et al.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients , 2005, European Respiratory Journal.

[65]  N. Høiby,et al.  Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[66]  P. Jones,et al.  Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. , 1997, The European respiratory journal.

[67]  P. Jones,et al.  Validation of the St. George's Respiratory Questionnaire in bronchiectasis. , 1997, American journal of respiratory and critical care medicine.

[68]  N. Høiby,et al.  Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis , 1997, Pediatric pulmonology.

[69]  John Gibson,et al.  Respiratory Health and Disease in Europe , 2013 .

[70]  C. Olveira,et al.  [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. , 2008, Archivos de bronconeumologia.

[71]  A. Smyth,et al.  Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. , 2006, The Cochrane database of systematic reviews.

[72]  D. Marchant,et al.  Risk factors. , 1994, Obstetrics and gynecology clinics of North America.

[73]  P. Cole.  Inflammation: a two-edged sword--the model of bronchiectasis. , 1986, European journal of respiratory diseases. Supplement.

[74]  Coletsos Pj.  Inflammation: a two-edged sword--the model of bronchiectasis. , 1986 .